Canopy Growth Corp - Asset Resilience Ratio
Canopy Growth Corp (WEED) has an Asset Resilience Ratio of 15.73% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Canopy Growth Corp PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Canopy Growth Corp's Asset Resilience Ratio has changed over time. See Canopy Growth Corp (WEED) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Canopy Growth Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Canopy Growth Corp.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$169.00 Million | 15.28% |
| Short-term Investments | CA$5.03 Million | 0.46% |
| Total Liquid Assets | CA$174.03 Million | 15.73% |
Asset Resilience Insights
- Good Liquidity Position: Canopy Growth Corp maintains a healthy 15.73% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Canopy Growth Corp Industry Peers by Asset Resilience Ratio
Compare Canopy Growth Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Canopy Growth Corp (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Canopy Growth Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 1.94% | CA$17.79 Million ≈ $12.87 Million |
CA$917.70 Million ≈ $663.85 Million |
-5.01pp |
| 2024-03-31 | 6.95% | CA$90.40 Million ≈ $65.39 Million |
CA$1.30 Billion ≈ $940.64 Million |
-6.17pp |
| 2023-03-31 | 13.13% | CA$320.14 Million ≈ $231.59 Million |
CA$2.44 Billion ≈ $1.76 Billion |
-2.92pp |
| 2022-03-31 | 16.05% | CA$900.97 Million ≈ $651.75 Million |
CA$5.62 Billion ≈ $4.06 Billion |
-11.25pp |
| 2021-03-31 | 27.30% | CA$1.86 Billion ≈ $1.35 Billion |
CA$6.82 Billion ≈ $4.94 Billion |
+8.39pp |
| 2020-03-31 | 18.91% | CA$1.30 Billion ≈ $938.17 Million |
CA$6.86 Billion ≈ $4.96 Billion |
-13.29pp |
| 2019-03-31 | 32.20% | CA$2.81 Billion ≈ $2.03 Billion |
CA$8.73 Billion ≈ $6.32 Billion |
+32.15pp |
| 2018-03-31 | 0.05% | CA$664.00K ≈ $480.33K |
CA$1.44 Billion ≈ $1.04 Billion |
-12.51pp |
| 2017-03-31 | 12.56% | CA$85.10 Million ≈ $61.56 Million |
CA$677.61 Million ≈ $490.17 Million |
-- |
About Canopy Growth Corp
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works. The company offers dried flower and pre-rolled joints; extracts and concentrates, such… Read more